Innate Pharma (IPHA) Enterprise Value (2017 - 2025)
Innate Pharma's (IPHA) quarterly Enterprise Value came in at -$39.9 million in Q4 2025, up 53.73% YoY from -$26.0 million in Q4 2024, and up 41.22% on a QoQ basis from -$67.9 million in Q2 2025.
Innate Pharma (IPHA) Enterprise Value (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Enterprise Value data on file, last reported at -$39.9 million in Q4 2025.
- Quarterly Enterprise Value rose 53.73% year-over-year to -$39.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.9 million (up 53.73% YoY) and the FY2025 annual result came in at -$39.9 million, up 53.73% from the prior year.
- Enterprise Value climbed to -$39.9 million in Q4 2025, from -$67.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$39.9 million in Q4 2025 to a low of -$143.7 million in Q2 2021.
- A 5-year average of -$100.5 million and a median of -$99.2 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value jumped 99.9% — and 2024, when it retreated 2.13%.
- Tracing IPHA's Enterprise Value over 5 years: stood at -$137.1 million in 2021, then climbed by 24.47% to -$103.5 million in 2022, then gained by 3.92% to -$99.5 million in 2023, then gained by 13.24% to -$86.3 million in 2024, then soared by 53.73% to -$39.9 million in 2025.
- The last three Enterprise Value figures came in at -$39.9 million (Q4 2025), -$67.9 million (Q2 2025), and -$86.3 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -39.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -39.94 Mn |
| Jun 30, 2025 | -67.95 Mn |
| Dec 31, 2024 | -86.31 Mn |
| Jun 30, 2024 | -98.86 Mn |
| Dec 31, 2023 | -99.48 Mn |
| Jun 30, 2023 | -96.79 Mn |
| Dec 31, 2022 | -103.54 Mn |
| Jun 30, 2022 | -131.62 Mn |
| Dec 31, 2021 | -137.09 Mn |
| Jun 30, 2021 | -143.69 Mn |
| Dec 31, 2020 | -180.80 Mn |
| Jun 30, 2020 | -147.74 Bn |
| Dec 31, 2019 | -242.26 Mn |
| Dec 31, 2018 | -191.22 Mn |
| Dec 31, 2017 | -136.71 Mn |